Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1075162 Target Snapshot

Uracil nucleotide/cysteinyl leukotriene receptor · SINGLE PROTEIN · Homo sapiens

134Compounds
58Assays
4Approved Drugs
156.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q13304. Use UniProt Q13304 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q13304 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Uracil nucleotide/cysteinyl leukotriene receptor as ChEMBL target CHEMBL1075162, mapped to UniProt Q13304. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Uracil nucleotide/cysteinyl leukotriene receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1075162
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13304
Uracil nucleotide/cysteinyl leukotriene receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Uracil nucleotide/cysteinyl leukotriene receptor is the right protein anchor across sources, using UniProt Q13304 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelUracil nucleotide/cysteinyl leukotriene receptor
UniProt AccessionQ13304
Component TypeProtein
Sequence Length367 aa

Uracil nucleotide/cysteinyl leukotriene receptor

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Uracil nucleotide/cysteinyl leukotriene receptor, mapped to UniProt Q13304. Sequence length is 367 aa.

Mapped IDQ13304
Review nameUracil nucleotide/cysteinyl leukotriene receptor
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

4
Approved
1
Phase II
Assay Mix

Activity Type Distribution

IC5048.0
KI8.0
EC5097.0
KD3.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1097652 10.44 EC50 0.036 Preclinical
CHEMBL1097279 9.15 IC50 0.7 Approved
CHEMBL1096742 8.85 EC50 1.4 Preclinical
CHEMBL1098419 8.77 EC50 1.7 Preclinical
CHEMBL31344 8.2 EC50 6.31 Preclinical
CHEMBL1098083 7.96 EC50 11.0 Preclinical
CHEMBL3132880 7.87 EC50 13.49 Preclinical
CHEMBL295718 7.69 EC50 20.42 Preclinical
CHEMBL4216761 7.55 EC50 27.9 Preclinical
CHEMBL4205476 7.49 EC50 32.1 Preclinical
Distribution

pChEMBL Value Distribution

30
5.0
24
5.5
14
6.0
9
6.5
2
7.0
4
7.5
1
8.0
2
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

CANGRELOR TETRASODIUM
CHEMBL1097279
Approved 2015
Assay Landscape

Assay Landscape

58
Total Assays
68
Tested Compounds
2
Assay Types
Functional — 40 assays, 68 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 39 68 5.8
single protein format 1 0
Binding — 18 assays, 7 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 12 7 5.6
assay format 4 0
single protein format 2 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine